Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › FATE

Fate Therapeutics

FATE Rare disease Lead: Phase 2 3 Biotech Distilled articles ↓ 20 filings & releases ↓ Cash $43.9M (Sep 30, 2026) ↓ 3 verdicts ↓
ImmunologyOncologyRenal Cell

Market cap $224M 121.6M shares (10-Q, Oct 30, 2026) × $1.84 close Nov 6, 2026

Most recent annual filing: 2026-02-26

Catalyst timeline

11 trackedQuarter catalyst calendar →
  1. FT839 Ph1 start2H 2026FT839 Ph1 start, 2H 2026, routine
  2. Autolus obe-cel CARLYSLE readout4Q 2026Autolus obe-cel CARLYSLE readout, 4Q 2026, material
  3. Kyverna miv-cel BLA filing4Q 2026Kyverna miv-cel BLA filing, 4Q 2026, notable
  4. FATE corporate updateNov 2026FATE corporate update, Nov 2026, routine
  5. FATE financing~Nov 2026FATE financing, ~Nov 2026, routine
  6. FT819 Ph1 readoutNov 9, 2026FT819 Ph1 readout, Nov 9, 2026, major
  7. FT836 readout1H 2027FT836 readout, 1H 2027, notable
  8. FT819 interim2H 2027FT819 interim, 2H 2027, material
  9. FT819 enrollment done1H 2028FT819 enrollment done, 1H 2028, notable
  10. Autolus obe-cel LUMINA readout2028Autolus obe-cel LUMINA readout, 2028, notable
  11. FT819 toplinemid-2028FT819 topline, mid-2028, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

Technology platforms

iPSC product platform

Induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapy platform combining multiplexed engineering of human iPSCs with single-cell selection to create clonal master iPSC lines for scalable manufacture of CAR T-cell and NK-cell products; focus areas include hematologic malignancies, solid tumors, and autoimmune diseases.

Sword and Shield

Novel alloimmune defense technology combining an alloimmune defense receptor (ADR) with CD58 knockout to enable CAR T-cell evasion of host alloreactive immune cells, designed to eliminate the need for conditioning chemotherapy; applied to iPSC-derived off-the-shelf CAR T-cell candidates in oncology and autoimmune diseases.

iPSC product platform · Ono Pharmaceutical

Induced pluripotent stem cell (iPSC) platform enabling production of off-the-shelf, multiplexed-engineered iPSC-derived cellular immunotherapies including CAR T-cell and CAR NK cell product candidates targeting solid tumor and hematologic disease antigens

Sword & Shield

Alloimmune Defense Receptor combined with CD58 knockout, designed to selectively eliminate and evade host allogeneic immune responses, promote functional persistence, and avoid need for conditioning chemotherapy in off-the-shelf iPSC-derived CAR T-cell therapies for autoimmune disease and hematologic malignancies

Discontinued (1)

Capital (as filed)

Cash
$43.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$95.2M Sep 30, 2026
Operating cash flow
−$27.8M quarter to Sep 30, 2026 (10-Q)
As stated in coverage
$139M cash, runway mid-2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Fate Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-09-25 Watch Fate Therapeutics (FATE) — Scientific Deep Dive for FT819, FT839 and Pipeline Products Fate has solved allogeneic CAR T manufacturing and FT819 has a clean safety profile, but the pivotal regimen's complete renal response rate is undisclosed, the trial reads out after the cash, and a dilutive financing is certain before topline data.
  2. 2026-10-27 Watch UPDATE: Fate Therapeutics (FATE) - The Denominator Arrives, Wearing a Disguise Fate published a denominator for the first time since 2025, but CRR and PERR are pooled, the pivotal regimen has only n=2, no dose split is given, and a dilutive financing remains imminent before topline.
  3. 2026-11-06 Watch UPDATE: Fate Therapeutics (FATE) - The Tap Is Open Fate opened a new $100M ATM with Leerink, runway guidance leans on an unsigned CIRM grant, and the pivotal-regimen CRR-only count remains missing; ACR is the defined test before any stance change.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (20)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 25, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)